Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non Operating Income (2021 - 2025)

Historic Other Non Operating Income for Agios Pharmaceuticals (AGIO) over the last 5 years, with Q3 2025 value amounting to $67000.0.

  • Agios Pharmaceuticals' Other Non Operating Income fell 9594.19% to $67000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 4730.12%. This contributed to the annual value of $6.5 million for FY2024, which is 713.46% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Other Non Operating Income stood at $67000.0, which was down 9594.19% from $523000.0 recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Other Non Operating Income ranged from a high of $6.5 million in Q2 2021 and a low of $67000.0 during Q3 2025
  • In the last 5 years, Agios Pharmaceuticals' Other Non Operating Income had a median value of $1.6 million in 2024 and averaged $2.0 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Other Non Operating Income soared by 3781.3% in 2024 and then tumbled by 9594.19% in 2025.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Other Non Operating Income stood at $3.3 million in 2021, then crashed by 58.48% to $1.4 million in 2022, then rose by 26.23% to $1.7 million in 2023, then decreased by 5.25% to $1.6 million in 2024, then crashed by 95.87% to $67000.0 in 2025.
  • Its Other Non Operating Income stands at $67000.0 for Q3 2025, versus $523000.0 for Q2 2025 and $1.3 million for Q1 2025.